We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current ALTHX market cap is 3.93M. The company's latest EPS is EUR -0.8800 and P/E is -0.58.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 583k | 295k | 5k | 1.19M | 298k |
| Operating Income | -7.41M | -6.12M | -9.49M | -6.28M | -7.66M |
| Net Income | -5.58M | -4.8M | -8.15M | -6.57M | -6.83M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 15.37M | 17.47M | 16.89M | 12.05M | 7.24M |
| Total Liabilities | 5.93M | 8.75M | 8.17M | 8.92M | 8.1M |
| Total Equity | 9.44M | 8.72M | 8.72M | 3.13M | -866k |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -4.97M | -5.68M | -6.15M | -5.37M | -6.36M |
| Investing | -2.11M | -252k | -150k | 324k | -60k |
| Financing | 1.35M | 7.69M | 7.61M | 1.63M | 2.22M |
| Market Cap | 3.93M |
| Price to Earnings Ratio | -0.58 |
| Price to Sales Ratio | 13.28 |
| Price to Cash Ratio | 3.3 |
| Price to Book Ratio | -4.57 |
| Dividend Yield | - |
| Shares Outstanding | 7.76M |
| Average Volume (1 week) | 33.75k |
| Average Volume (1 Month) | 21.9k |
| 52 Week Change | -58.11% |
| 52 Week High | 1.348 |
| 52 Week Low | 0.46 |
| Spread (Intraday) | 0.01 (2.17%) |
| Company Name | Theranexus SA |
| Address |
pepiniere laennec 60 avenue rockefeller lyon, rhone 69008 |
| Website | https://www.theranexus.com |
| Industry | medicinal chems,botanicl pds (2833) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
